% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gaito:271244,
author = {S. Gaito and E. J. Hwang and A. France and M. C. Aznar and
N. Burnet and A. Crellin and A. L. Holtzman and D. J.
Indelicato and B. Timmerman$^*$ and G. A. Whitfield and E.
Smith},
title = {{O}utcomes of {P}atients {T}reated in the {UK} {P}roton
{O}verseas {P}rogramme: {C}entral {N}ervous {S}ystem
{G}roup.},
journal = {Clinical oncology},
volume = {35},
number = {5},
issn = {0936-6555},
address = {[Erscheinungsort nicht ermittelbar]},
publisher = {Saunders},
reportid = {DKFZ-2023-00376},
pages = {283-291},
year = {2023},
note = {2023 May;35(5):283-291},
abstract = {In 2008, the UK National Health Service started the Proton
Overseas Programme (POP), to provide access for proton beam
therapy (PBT) abroad for selected tumour diagnoses while two
national centres were being planned. The clinical outcomes
for the patient group treated for central nervous system
(CNS), base of skull, spinal and paraspinal malignancies are
reported here.Since the start of the POP, an agreement
between the National Health Service and UK referring centres
ensured outcomes data collection, including overall
survival, local tumour control and late toxicity data.
Clinical and treatment-related data were extracted from this
national patient database. Grade ≥3 late toxicities were
reported following Common Terminology Criteria for Adverse
Events (CTCAE) v 4.0 definition, occurring later than 90
days since the completion of treatment.Between 2008 and
September 2020, 830 patients were treated within the POP for
the above listed malignancies. Overall survival data were
available for 815 patients and local control data for 726
patients. Toxicity analysis was carried out on 702 patients,
with patients excluded due to short follow-up (<90 days)
and/or inadequate toxicity data available. After a median
follow-up of 3.34 years (0.06-11.58), the overall survival
was $91.2\%.$ The local control rate was $85.9\%$ after a
median follow-up of 2.81 years (range 0.04-11.58). The
overall grade ≥3 late toxicity incidence was $11.97\%,$
after a median follow-up of 1.72 years (0.04-8.45). The
median radiotherapy prescription dose was 54 GyRBE
(34.8-79.2).The results of this study indicate the safety of
PBT for CNS tumours. Preliminary clinical outcomes following
PBT for paediatric/teen and young adult and adult CNS
tumours treated within the POP are encouraging, which
reflects accurate patient selection and treatment quality.
The rate of late effects compares favourably with published
cohorts. Clinical outcomes from this patient cohort will be
compared with those of UK-treated patients since the start
of the national PBT service in 2018.},
keywords = {Brain (Other) / late toxicities (Other) / paediatric
(Other) / proton beam therapy (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36804292},
doi = {10.1016/j.clon.2023.01.024},
url = {https://inrepo02.dkfz.de/record/271244},
}